About IMI

The European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have jointly established a new, non-profit European Community body, the Innovative Medicines Initiative Joint Undertaking (IMI JU), an unique public -  private partnership.

This joint undertaking will award research grants to European public - private collaborations conducting innovative research projects that focus on implementing the recommendations of the IMI Research Agenda.

The Research Agenda is a multiannual plan. It is based on the Strategic Research Agenda developed by the European Technology Platform on Innovative Medicines which identified principal research bottlenecks in the biopharmaceutical R&D process and sets forth recommendations to overcome these bottlenecks by focusing on four areas:

• Predicting safety - addresses bottlenecks related to accurately evaluating the safety of a compound during the pre-clinical phase of the development process, but also impacts the later phases in clinical development
• Predicting efficacy - addresses bottlenecks in the ability to predict how a drug will interact in humans and how it may produce a change in function
• Knowledge management - this addresses the more effective utilisation of information and data for predicting safety and efficacy
• Education and training - this closes existing training gaps in the drug development process.

Get the IMI research agenda.

For a short MVA presentation of the Strategic research agenda.